KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Consolidated Net Income (2016 - 2025)

Sarepta Therapeutics has reported Consolidated Net Income over the past 15 years, most recently at $352.8 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 122.23% year-over-year to $352.8 million; the TTM value through Dec 2025 reached -$77.7 million, down 133.07%, while the annual FY2025 figure was -$77.7 million, 133.07% down from the prior year.
  • Consolidated Net Income for Q4 2025 was $352.8 million at Sarepta Therapeutics, up from -$179.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $352.8 million in Q4 2025 and troughed at -$516.7 million in Q1 2023.
  • A 5-year average of -$29.8 million and a median of -$32.4 million in 2023 define the central range for Consolidated Net Income.
  • On a YoY basis, Consolidated Net Income climbed as much as 2940.57% in 2025 and fell as far as 1338.98% in 2025.
  • Year by year, Consolidated Net Income stood at $249.3 million in 2021, then plummeted by 42.99% to $142.1 million in 2022, then surged by 130.0% to $326.9 million in 2023, then tumbled by 51.44% to $158.8 million in 2024, then soared by 122.23% to $352.8 million in 2025.
  • Business Quant data shows Consolidated Net Income for SRPT at $352.8 million in Q4 2025, -$179.9 million in Q3 2025, and $196.9 million in Q2 2025.